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evidence that Spiro had greater effects on hsCRP than placebo, suggesting that reduced
inflammation was not a major mechanism underlying the clinical benefit of Spiro in this
setting.
1108-122 Cost-Effectiveness of Eplerenone in Patients With Heart 
Failure Postmyocardial Infarction
William S. Weintraub, Zefeng Zhang, Elizabeth Mahoney, Richard Willke, John Spertus, 
Bertram Pitt, Emory University, Atlanta, GA
Background: Aldosterone blockade with eplerenone prolonged life in the setting of heart
failure (HF) post myocardial infarction (MI) in the EPHESUS trial. 6,632 patients in 37
countries with HF post-MI were randomized to eplerenone 25-50 mg/day vs placebo,
mean follow-up 16 with 478 deaths in the eplerenone group, 554 with placebo group (rel-
ative risk 0.85, 95% CI 0.75 to 0.96). We consider the cost-effectiveness of eplerenone
based on EPHESUS.
Methods: Trial wide efficacy and resource utilization were used. Unit costs in multiple
countries were applied to hospitalizations and ER visits by DRG and outpatient proce-
dures. Medication use was costed using average wholesale price. Initial hospitalization
costs were not included in the base case as study drug was initiated towards the end of
this hospitalization. Eplerenone is not yet marketed; drug cost will be available in late
2003 or early 2004. Life expectancy was estimated from Framingham data, discounted
3%. A similar analysis based on the Worcester Heart Attack Registry will be presented as
well. Results: 
Cost-effectiveness based on Ephesus trial results with Framingham and Worcester sur-
vival models will be presented for the United States and the Netherlands.
Conclusions: Independently of drug costs, aldosterone blockade with eplerenone in the
setting of heart failure post-MI is a dominant strategy, preventing events, prolonging life,
and lowering resource use without increasing cost. Cost-effectiveness with drug cost in-
cluded will be presented.
1108-123 The Effect of Eplerenone on Markers of Cardiac 
Fibrosis: Insights From EPHESUS
Faiez Zannad, Jean-Marie Ketelslegers, Ernesto L. Schiffrin, Gordon Williams, Susan 
Garthwaite, Weizhong He, Rajiv Patni, Bertram Pitt, Clinical Investigation Center 
INSERM-CHU de Nancy Hôpital Jeanne d'Arc, Dommartin-les Toul Cedex, France
Background: Chronic heart failure patients with elevated markers of cardiac fibrosis
have an increased risk of death; aldosterone blockade reduces this risk (Circ
2000;102:2700-2706). EPHESUS showed that selective aldosterone blockade with
eplerenone reduced total mortality by 15% (P=0.008) and CV mortality/hospitalization by
13% (P=0.002) vs placebo when added to standard care in post-MI patients with systolic
left ventricular dysfunction (SLVD) (NEJM 2003;348:1309-21). This substudy evaluated
the correlation between procollagen type III amino-terminal peptide (PIIINP) and out-
comes in patients treated with eplerenone vs placebo.
Methods: There were 476 patients in the substudy. Baseline blood samples were drawn
with patients in a seated position, the morning of randomization (mean = 7, range 3-14
days, after index MI). Subsequent levels were drawn at Week 4, and Months 3, 6, and 9.
Results: Baseline PIIINP levels were elevated among nonsurvivors in both arms (non-
survivors 4.14 µg/L vs survivors 3.98 µg/L), and were associated with an increased risk
of negative outcomes. At baseline, PIIINP levels were 4.0 µg/L in eplerenone and pla-
cebo groups. Eplerenone significantly reduced PIIINP levels over time. Changes were
statistically different from placebo beginning at Week 4 (eplerenone 4.1 µg/L [+4%] vs
placebo 4.5 µg/L [+15%]; P<0.001). By Month 9, eplerenone reduced PIIINP levels from
baseline -11.5% vs -2.3% for placebo patients (P=0.002).
Conclusions: Eplerenone decreased PIIINP levels, a marker of cardiac collagen deposi-
tion associated with an increased risk of total mortality and CV mortality/hospitalization.
These findings suggest an association between the action of eplerenone on aldosterone,
myocardial fibrosis, and improved outcomes, and support the prognostic value of PIIINP
levels in patients with post-MI SLVD.
1108-124 Effect of Exercise Training on Sleep Disordered 
Breathing in Severe Heart Failure Patients
Dov Freimark, Peretz Lavie, Meirav Ingbir, Ehud Schwammenthal, Michael Motro, 
Yehuda Adler, Heart Failure Clinic, Sheba Medical Center, Tel hashomer, Israel, Cardiac 
Rehabilitation Institute, Sheba Medical Center, Tel Hashomer, Israel
Background: Chene-Stokes respiration (CSR) is common in patients with congestive
heart failure (CHF) and is associated with nocturnal oxygen desaturation, sleep disrup-
tion, impaired exercise tolerance and prognosis. Exercise training (ET) has been shown
to be effective in restoring functional capacity and improving quality of life in these
patients. The aim of our study was to determine the impact of ET on CSR in severe CHF
patients.
Methods: Forty-four severe stable CHF patients (mean LVEF 21±7%) participated in an
18 week ET program. Thirty of them underwent an initial sleep study prior to the ET, and
of these 25 underwent an additional sleep study at the end of the ET. A modified Bruce
exercise test was performed by all patients at the beginning and end of the ET period.
Based on the initial sleep recordings patients were divided into two groups with (N=18,
respiratory disturbance index (RDI) of >20 events/hr, Group A) and without (N=12, RDI of
<19 events/hr, Group B) significant CSR. A follow-up post ET sleep study was completed
by 15 patients from Group A and 10 from Group B.
Results: There was no significant difference between Groups A and B in pre-training
exercise test duration (mins), 5.9±3.9 versus 4.6±3.0, p=0.34, respectively. Exercise
duration improved significantly post ET in both Groups, 10.6±2.3 mins, p<0.01 (Group A)
and 8.7±2.7 mins, p<0.01 (Group B). A significant reduction in CSR was noted in Group
A, RDI 38.3±18.1 before ET, compared to 22.6±15.9 after training, p=0.005. However, the
number of episodes did not change in Group B, RDI 12.0±3.1 before and 16.3±7.8 after
training, p=0.19.
Conclusion: Severely ill CHF patients with severe CSR can benefit from ET.
1108-125 Can the Response to Exercise Training Be Predicted in 
Patients With Heart Failure?
Neil Smart, Leanne Short, Brian Haluska, Thomas H. Marwick, University of 
Queensland, Brisbane, Australia
Background. Exercise training in heart failure (CHF) has favorable effects on quality of
life, LV function and functional capacity, but some pts do not respond and supervision
makes this approach resource-intensive. We sought to identify pts most likely to benefit,
thus permitting optimal use of resources.
Methods. A 16 week program of aerobic training (cycle ergometer 3 times/week, at 70%
Peak VO2) was undertaken by 32 pts (30 male, age 63±11 y) with baseline EF <35%
(mean 27±8%) and peak VO2 12±4 ml/kg/min. The etiology of CHF was ischemic heart
disease in 20 pts (63%). At baseline, 8- and 16 -weeks, pts underwent 2D echo, meta-
bolic exercise testing and quality of life evaluation with Minnesota Living with Heart Fail-
ure (MLWHF) and Hare-Davis Cardiac Depression (HD) questionnaires.
Results. Both MLWHF and HD scores improved at 8 and 16 wks (p=0.001). Resting EF
improved by 13% at 8 wks (p=0.009) and 17% at 16 weeks (p=0.05). Peak VO2
increased at 8 wks (to 13±4, p=0.04) and at 16 wks (15±4, p<0.001). Change of VO2 at
16 weeks was predicted by baseline and 8 wk peak VO2 (model r2 = 0.77, see figure).
Conclusions. QOL, EF and peak VO2 were improved by training, although QOL and EF
changes plateau in the first 8 weeks while further changes in peak VO2 occur between 8
and 16 wks. Change in peak VO2 at 16 wks may be predicted from baseline and 8 wk
peak VO2 data, suggesting a means of selecting pts for this resource intensive therapy. 
hsCRP Placebo p value hsCRP Spiro p value Placebo vs Spiro
T0 0.67 [0.46-0.97] 0.61 [0.45-0.82] 0.54
T3 0.50 [0.34-0.73] 0.39 [0.28-0.53] 0.25
T6 0.37 [0.25-0.54] 0.31 [0.22-0.43] 0.30
T3/T0 0.78 [0.54-1.12] 0.18 0.67 [0.44-1.01] 0.053 0.75
T6/T0 0.60 [0.39-0.92] 0.02 0.59 [0.39-0.91] 0.02 0.80
Placebo Eplerenone Difference 95% CI
Initial Hospital Costs $6,164 $6,140 -$24 -$46,-$1
Re-Hospitalization Costs $8,271 $8,073 -$198 -$959, $482
Medication Costs(exclusive of 
eplerenone)
$3,314 $3,382 $67 -$51, $192
Outpatient Tests $534 $568 $34 -$34, $104
ER Visits $47 $43 -$4 -$10, $2
Total Follow-up Costs $12,167 $12,065 -$101 -$859, $669
F/u Heart Failure 
Hospitalizations
0.1862 0.1437 -0.0425 -0.0694, -0.0162
Total f/u Hospitalizations 0.9007 0.8481 -0.0526 -0.1250, 0.0187
Life Years (in trial) 1.30 1.33 0.0304 0.0026, 0.0567
Lost Life Expectancy in Years 
(Framingham)
0.6404 0.5390 0.1014 0.0306, 0.1740
